PHRR200909-002920
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease
Novartis Healthcare Philippines, Inc.·Phase 3·Philippine Health Research RegistryTerminated
Study focus
- Disease/Condition
- Cardiovascular Disease
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Novartis Healthcare Philippines, Inc.
- Funder
- Novartis Pharma Services AG
- Location
- Australia;China;Denmark;Germany;Hong;Kong;India;Japan;Malaysia;Poland;Singapore;United;States
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Jun 26, 2019
- End date
- Jul 30, 2023
ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease
Data source
- Registry
- Philippine Health Research Registry
- Trial ID
- PHRR200909-002920
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for PHRR200909-002920 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novartis Healthcare Philippines, Inc. and is currently Terminated. The study focuses on Cardiovascular Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.